Research and experimental development on natural sciences and engineering
ARXX THERAPEUTICS AS
Revenue 2024
NOK 5.0m
Operating profit
NOK −66.8m
Equity
NOK 13.5m
Incorporated
2015
Share capital
NOK 5.5m
Key figures · 2024
Current ratio
1.18
Equity ratio
15.9%
Key figures over time · 2024
| Key figures | 2024 | Trend |
|---|---|---|
| Lønnsomhet | ||
| Operating margin (%%) | -1336.8% | |
| Net margin (%%) | -1340.8% | |
| Return on assets (%%) | -78.6% | |
| Likviditet | ||
| Current ratio | 1.18 | |
| Working capital | 13.2m | |
| Soliditet | ||
| Equity ratio (%%) | 15.9% | |
| Debt-to-equity ratio | 5.30 | |
Source: Biztrac.no · Data from the Brønnøysund Register Centre and the Norwegian Tax Administration · Last updated 15.06.2026.